Form 4: Nuvalent CFO Balcom Sells Shares, Receives New Equity

Nuvalent Inc.'s Chief Financial Officer, Alexandra Balcom, sold shares to cover tax obligations from vested equity awards and simultaneously received new grants of restricted stock units and stock options.

Summary

• Alexandra Balcom, Nuvalent Inc.'s Chief Financial Officer, engaged in multiple transactions involving the company's Class A Common Stock.
• On January 5, 2026, Balcom sold a total of 4,236 shares across four transactions at weighted average prices ranging from $96.06 to $98.52.
• On January 6, 2026, an additional 3,181 shares were sold across three transactions at weighted average prices ranging from $96.75 to $98.40.
• These sales, totaling 7,417 shares, were executed under a Rule 10b5-1 plan established on December 6, 2023, specifically to cover tax withholding obligations arising from the vesting of prior equity awards.
• On January 7, 2026, Balcom acquired 17,500 shares of Class A Common Stock through Restricted Stock Units (RSUs) at a price of $0.00, which will vest in three equal annual installments.
• Also on January 7, 2026, Balcom was granted 17,500 stock options with an exercise price of $106.82, vesting over four years in equal monthly installments and expiring on January 7, 2036.
• Following these transactions, Balcom directly beneficially owns 99,233 shares of non-derivative Class A Common Stock and 17,500 derivative stock options.

Sentiment

Score: 6

Explanation: The filing indicates routine insider transactions. While there are sales, they are for tax purposes and are offset by new equity grants (RSUs and stock options), suggesting continued executive incentive and alignment with long-term company performance.

Positives

• Alexandra Balcom, CFO, received a grant of 17,500 Restricted Stock Units (RSUs) at a $0.00 price, representing future equity ownership and aligning her interests with long-term company performance.
• Balcom also received a grant of 17,500 stock options with an exercise price of $106.82, providing a further incentive for future company performance and shareholder value creation.

Negatives

• Alexandra Balcom sold a total of 7,417 shares of Class A Common Stock across multiple transactions on January 5 and 6, 2026.
• The sales were executed at weighted average prices ranging from $96.06 to $98.52, reducing her direct non-derivative beneficial ownership.

Future Outlook

NA

Industry Context

This filing reflects routine insider equity transactions common in the biotechnology or pharmaceutical industry, where executive compensation often includes significant equity components that vest over time, leading to periodic sell-to-cover transactions for tax obligations.

Stakeholder Impact

• Shareholders: The sale of shares by a CFO, even for tax purposes, slightly increases the float. The grant of new equity awards aligns management's interests with long-term shareholder value creation, potentially fostering confidence.
• Employees: The equity grants to the CFO are part of standard executive compensation, which can serve as a model for broader employee incentive programs within the company.

Next Steps

• RSUs will vest in three equal annual installments following January 7, 2026, subject to continued service to Nuvalent, Inc.
• Stock options will vest over four years following January 7, 2026, in equal monthly installments, subject to continued service to Nuvalent, Inc.

Key Dates

Recommendation

This Form 4 details routine insider transactions where the CFO sold shares to cover tax obligations from vested equity awards and simultaneously received new equity grants (RSUs and stock options). These actions are standard for executive compensation and do not indicate a change in the company's fundamental outlook or the executive's confidence. Therefore, the filing itself does not provide a basis for a change in investment recommendation.

Keywords

Nuvalent Inc., NUVL, Form 4, Insider Trading, Alexandra Balcom, Chief Financial Officer, Equity Awards, Stock Options, Restricted Stock Units, Rule 10b5-1, Sell-to-Cover, Tax Withholding